Co-Authors
This is a "connection" page, showing publications co-authored by Alex Soriano and Carolina Garcia-Vidal.
Connection Strength
3.255
-
Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS One. 2018; 13(6):e0199531.
Score: 0.774
-
Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis. 2022 01 07; 74(1):127-132.
Score: 0.247
-
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. J Antimicrob Chemother. 2021 11 12; 76(12):3296-3302.
Score: 0.245
-
Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021 Jun; 34(3):238-244.
Score: 0.235
-
Real-life use of remdesivir in hospitalized patients with COVID-19. Rev Esp Quimioter. 2021 Apr; 34(2):136-140.
Score: 0.233
-
Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. Lancet Reg Health Eur. 2021 Apr; 3:100041.
Score: 0.231
-
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021 Jan; 27(1):83-88.
Score: 0.224
-
Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. Antimicrob Agents Chemother. 2018 11; 62(11).
Score: 0.198
-
[Clinical features and outcome in patients with mucormycosis in a tertiary hospital (2012-2016)]. Rev Iberoam Micol. 2018 Jul - Sep; 35(3):162-166.
Score: 0.197
-
Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. Clin Microbiol Infect. 2019 Apr; 25(4):447-453.
Score: 0.195
-
Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. BMJ Open. 2021 08 17; 11(8):e040775.
Score: 0.060
-
Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. Infect Dis Ther. 2021 Sep; 10(3):1407-1418.
Score: 0.059
-
Experience with the use of siltuximab in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021 Aug; 34(4):337-341.
Score: 0.059
-
Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients. PLoS One. 2021; 16(4):e0240200.
Score: 0.059
-
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents. 2019 Apr; 53(4):520-524.
Score: 0.050
-
Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018 12; 15:136-139.
Score: 0.049
-
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis-authors' response. J Antimicrob Chemother. 2018 06 01; 73(6):1732-1733.
Score: 0.048
-
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis. J Antimicrob Chemother. 2017 Dec 01; 72(12):3443-3452.
Score: 0.047
-
Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. PLoS One. 2017; 12(8):e0182436.
Score: 0.045